Serum proteomic patterns for detection of prostate cancer |
| |
Authors: | Petricoin Emanuel F Ornstein David K Paweletz Cloud P Ardekani Ali Hackett Paul S Hitt Ben A Velassco Alfredo Trucco Christian Wiegand Laura Wood Kamillah Simone Charles B Levine Peter J Linehan W Marston Emmert-Buck Michael R Steinberg Seth M Kohn Elise C Liotta Lance A |
| |
Institution: | Food and Drug Administration (FDA)-National Cancer Institute (NCI) Clinical Proteomics Program, Department of Therapeutic Proteins/Center for Biologics Evaluation and Research (CBER), Bethesda, MD, USA. petricoin@cber.fda.gov |
| |
Abstract: | Pathologic states within the prostate may be reflected by changes in serum proteomic patterns. To test this hypothesis, we analyzed serum proteomic mass spectra with a bioinformatics tool to reveal the most fit pattern that discriminated the training set of sera of men with a histopathologic diagnosis of prostate cancer (serum prostate-specific antigen PSA] > or =4 ng/mL) from those men without prostate cancer (serum PSA level <1 ng/mL). Mass spectra of blinded sera (N = 266) from a test set derived from men with prostate cancer or men without prostate cancer were matched against the discriminating pattern revealed by the training set. A predicted diagnosis of benign disease or cancer was rendered based on similarity to the discriminating pattern discovered from the training set. The proteomic pattern correctly predicted 36 (95%, 95% confidence interval CI] = 82% to 99%) of 38 patients with prostate cancer, while 177 (78%, 95% CI = 72% to 83%) of 228 patients were correctly classified as having benign conditions. For men with marginally elevated PSA levels (4-10 ng/mL; n = 137), the specificity was 71%. If validated in future series, serum proteomic pattern diagnostics may be of value in deciding whether to perform a biopsy on a man with an elevated PSA level. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|